Fetuses of women with alloantibodies to RhD (D) are at risk from hemolytic disease of the
fetus and newborn, but only if the fetal red cells are D‐positive. In such pregnancies, it is …

Please cite this paper as: Scheffer P, van der Schoot C, Page‐Christiaens G, de Haas M.
Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised …

Incompatibility of red blood cell blood group antigens between a pregnant woman and her
fetus can cause maternal immunization and, consequently, hemolytic disease of the fetus …

OBJECTIVE: The purpose of this study was to determine the reported diagnostic accuracy,
the validity, and the current limitations of fetal Rh genotyping from peripheral maternal blood …

Objective Prenatal diagnostic assays have been developed using free fetal DNA circulating
in the maternal blood of pregnant women. Efficient DNA extraction is crucial for a robust …

Background Non-invasive prenatal testing of cell-free fetal DNA (cffDNA) in maternal plasma
can predict the fetal RhD type in D negative pregnant women. In Denmark, routine antenatal …

Detection and characterization of circulating cell-free fetal DNA (cffDNA) from maternal
circulation requires an extremely sensitive and precise method due to very low cffDNA …

Background Non-invasive foetal RHD genotyping can predict haemolytic disease of the
foetus and the newborn in pregnancies with anti-D alloantibodies and also avoid antenatal …

Alloimmunization against the RhD antigen is the most common cause of hemolytic disease
of the fetus and newborn. Antenatal anti-D prophylaxis in addition to postnatal anti-D …

Objectives Detection of free fetal DNA (ffDNA) in maternal blood during pregnancy has given
rise to the possibility of developing new noninvasive approaches for early prenatal …